Toll Free: 1-888-928-9744

Women Infertility - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 190 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Women Infertility - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Women Infertility - Overview 9 Women Infertility - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 16 Products under Development by Universities/Institutes 20 Women Infertility - Therapeutics Assessment 21 Assessment by Target 21 Assessment by Mechanism of Action 24 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Women Infertility - Companies Involved in Therapeutics Development 31 4P Therapeutics LLC 31 AbbVie Inc 31 Addex Therapeutics Ltd 32 AlphaMab Co Ltd 32 APAvadis Biotechnologies Srl 33 ASKA Pharmaceutical Co Ltd 33 Astellas Pharma Inc 34 Bayer AG 34 Dong-A Socio Holdings Co Ltd 35 Dongkook Pharmaceutical Co Ltd 36 ElexoPharm GmbH 36 EndoCeutics Inc 37 Enteris BioPharma Inc 37 Evotec AG 38 Ferring International Center SA 38 Forendo Pharma Ltd 39 Glycotope GmbH 39 Isifer AB 40 Kissei Pharmaceutical Co Ltd 40 Lipicard Technologies Ltd 41 Livzon Pharmaceutical Group Inc 41 Luye Pharma Group Ltd 42 Merck & Co Inc 42 Navya Biologicals Pvt Ltd 43 Nippon Shinyaku Co Ltd 43 Nora Therapeutics Inc 44 ObsEva SA 44 Ogeda SA 45 Orphagen Pharmaceuticals Inc 45 Pangen Biotech Inc. 46 Pantec Biosolutions AG 46 PharmaEssentia Corp 47 Philogen SpA 47 Repros Therapeutics Inc 48 Richter Gedeon Nyrt 48 SK Chemicals Co Ltd 49 Takeda Pharmaceutical Company Ltd 49 TocopheRx Inc 50 ValiRx Plc 50 Viramal Ltd 51 Zydus Cadila Healthcare Ltd 51 Women Infertility - Drug Profiles 52 acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 52 ADX-68692 - Drug Profile 53 AKP-501 - Drug Profile 54 ASP-1707 - Drug Profile 55 barusiban - Drug Profile 56 BAY-1128688 - Drug Profile 57 BAY-1158061 - Drug Profile 58 Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile 59 Biosimilar 5 for Infertility and Oncology - Drug Profile 60 Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile 61 Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile 62 choriogonadotropin alfa biosimilar - Drug Profile 63 choriogonadotropin alfa biosimilar - Drug Profile 64 danazol - Drug Profile 65 Drug 1 for Endometriosis - Drug Profile 66 Drug 2 for Endometriosis - Drug Profile 67 Drug 3 for Endometriosis - Drug Profile 68 Drug 4 for Endometriosis - Drug Profile 69 Drug 5 for Endometriosis - Drug Profile 70 Drug to Antagonize P2X3 for Endometriosis - Drug Profile 71 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 72 Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile 73 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 74 EC-313 - Drug Profile 75 elagolix sodium - Drug Profile 76 EVE-104 - Drug Profile 81 FE-999310 - Drug Profile 82 fezolinetant - Drug Profile 83 follicle stimulating hormone biosimilar - Drug Profile 86 follitropin alfa biosimilar - Drug Profile 87 follitropin alfa biosimilar - Drug Profile 89 follitropin alfa biosimilar - Drug Profile 90 follitropin delta - Drug Profile 91 FP-5677 - Drug Profile 93 FSH-GEX - Drug Profile 94 goserelin biosimilar - Drug Profile 96 goserelin ER - Drug Profile 97 Isifera - Drug Profile 98 kisspeptin-54 - Drug Profile 99 KLH-2109 - Drug Profile 100 KN-015 - Drug Profile 102 leuprolide acetate - Drug Profile 103 LM-001 - Drug Profile 104 LM-002 - Drug Profile 105 LT-6121 - Drug Profile 106 menotropins - Drug Profile 107 MIA-602 - Drug Profile 108 MK-8389 - Drug Profile 109 Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile 110 NAV-013 - Drug Profile 111 NS-580 - Drug Profile 112 NT-100 - Drug Profile 113 OBE-001 - Drug Profile 115 PEG-FSH - Drug Profile 118 Peptide to Agonize FSH Receptor for Women Infertility - Drug Profile 119 Peptides for Endometriosis and Hepatic Tumor - Drug Profile 120 Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 121 PGL-1001 - Drug Profile 122 PGL-2001 - Drug Profile 123 progesterone - Drug Profile 124 Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 125 relugolix - Drug Profile 126 SKI-2670 - Drug Profile 129 Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 130 Small Molecules for Female Infertility - Drug Profile 131 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 132 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 133 Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology - Drug Profile 134 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 135 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 136 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 137 SR-16234 - Drug Profile 138 STI-2833 - Drug Profile 139 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 140 TAK-448 - Drug Profile 141 telapristone acetate - Drug Profile 143 Tetravil - Drug Profile 152 TOP-001 - Drug Profile 154 TOP-002 - Drug Profile 155 triptorelin - Drug Profile 156 triptorelin acetate ER - Drug Profile 157 triptorelin biosimilar - Drug Profile 158 VAL-201 - Drug Profile 159 VAL-301 - Drug Profile 164 vilaprisan - Drug Profile 165 VPE-001 - Drug Profile 166 VPEA-004 - Drug Profile 167 Women Infertility - Dormant Projects 168 Women Infertility - Discontinued Products 171 Women Infertility - Product Development Milestones 172 Featured News & Press Releases 172 Appendix 183 Methodology 183 Coverage 183 Secondary Research 183 Primary Research 183 Expert Panel Validation 183 Contact Us 183 Disclaimer 184
List of Tables
Number of Products under Development for Women Infertility, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Women Infertility - Pipeline by 4P Therapeutics LLC, H1 2017 Women Infertility - Pipeline by AbbVie Inc, H1 2017 Women Infertility - Pipeline by Addex Therapeutics Ltd, H1 2017 Women Infertility - Pipeline by AlphaMab Co Ltd, H1 2017 Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H1 2017 Women Infertility - Pipeline by ASKA Pharmaceutical Co Ltd, H1 2017 Women Infertility - Pipeline by Astellas Pharma Inc, H1 2017 Women Infertility - Pipeline by Bayer AG, H1 2017 Women Infertility - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 Women Infertility - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017 Women Infertility - Pipeline by ElexoPharm GmbH, H1 2017 Women Infertility - Pipeline by EndoCeutics Inc, H1 2017 Women Infertility - Pipeline by Enteris BioPharma Inc, H1 2017 Women Infertility - Pipeline by Evotec AG, H1 2017 Women Infertility - Pipeline by Ferring International Center SA, H1 2017 Women Infertility - Pipeline by Forendo Pharma Ltd, H1 2017 Women Infertility - Pipeline by Glycotope GmbH, H1 2017 Women Infertility - Pipeline by Isifer AB, H1 2017 Women Infertility - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Women Infertility - Pipeline by Lipicard Technologies Ltd, H1 2017 Women Infertility - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017 Women Infertility - Pipeline by Luye Pharma Group Ltd, H1 2017 Women Infertility - Pipeline by Merck & Co Inc, H1 2017 Women Infertility - Pipeline by Navya Biologicals Pvt Ltd, H1 2017 Women Infertility - Pipeline by Nippon Shinyaku Co Ltd, H1 2017 Women Infertility - Pipeline by Nora Therapeutics Inc, H1 2017 Women Infertility - Pipeline by ObsEva SA, H1 2017 Women Infertility - Pipeline by Ogeda SA, H1 2017 Women Infertility - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017 Women Infertility - Pipeline by Pangen Biotech Inc., H1 2017 Women Infertility - Pipeline by Pantec Biosolutions AG, H1 2017 Women Infertility - Pipeline by PharmaEssentia Corp, H1 2017 Women Infertility - Pipeline by Philogen SpA, H1 2017 Women Infertility - Pipeline by Repros Therapeutics Inc, H1 2017 Women Infertility - Pipeline by Richter Gedeon Nyrt, H1 2017 Women Infertility - Pipeline by SK Chemicals Co Ltd, H1 2017 Women Infertility - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Women Infertility - Pipeline by TocopheRx Inc, H1 2017 Women Infertility - Pipeline by ValiRx Plc, H1 2017 Women Infertility - Pipeline by Viramal Ltd, H1 2017 Women Infertility - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Women Infertility - Dormant Projects, H1 2017 Women Infertility - Dormant Projects, H1 2017 (Contd..1), H1 2017 Women Infertility - Dormant Projects, H1 2017 (Contd..2), H1 2017 Women Infertility - Discontinued Products, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify